Skyhawk Therapeutics, Inc. logo
Skyhawk Therapeutics, Inc. logo

Skyhawk Therapeutics, Inc.

skyhawktx.com
skyhawktx.com • 11-50 employees • Founded 2018 • Likely startup • New
11-50 employees • Founded 2018 • Likely startup • New
Actively hiring
Science & Engineering
Health Care
Biotechnology
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Team
11-50
employees, estimated range
Backers
1
Good Growth Capital
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2018 Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Good Growth Capital fund
Similar startupsby what they do, their industry and backers
Paradigm HealthSeries B $78M · 9 mo ago • 201-500 employees • 10 roles
Paradigm Health is the AI-native clinical trial platform connecting biopharma sponsors with a research-ready provider network across 2,100…
martini.ai
A new phase for martini.ai. As of February 13, martini.ai has concluded its current operations as part of a transition into an exciting new…
Phi OpticsVenture round $200k · 8 yr ago
About Phi Optics Phi Optics combines phase imaging with low-coherence interferometry and holography in a common-path geometry. Phase…
SynapticureSeries A $25M · 22 mo ago • Founded 2019 • 51-200 employees • 3 roles
Synapticure provides personalized virtual care to people living with Alzheimer’s and related Dementia, Huntington's, Parkinson’s, ALS and…
IgGenix# Life Science/Healthcare# North America51-200 employees
Clinical Trials. A Phase 1, randomised, double-blind clinical study to evaluate the safety and tolerability of IGNX001, an injectable…
Zilliqa11-50 employees
Zilliqa is building the check that comes before settlement, confirming two parties are permitted to transact, on any chain. See the…

Overview

Fifteen-month data readout from Phase 1/2 Huntington's trial. Skyhawk shares its fifteen-month final dataset for its Phase 1/2 SKY-0515 Huntington's trial, including cUHDRS and its subcomponents, safety, and biomarker findings.